pipette
ENEnglish

No Heavy Drinking Days and Percentage of Days Abstinent in a Randomized Trial of Adjunctive Ketamine for Alcohol Use Disorder: Secondary Analysis of the KARE Trial

C. J. Morgan, D. J. Nutt

PreprintAfirmaciones fuertes, leer con cuidadoUso en el mundo real

En palabras de los autores

In the KARE trial, 96 adults with severe alcohol use disorder, abstinent following detoxification, were randomised in a 2x2 factorial design to 3 weekly infusions of ketamine (0.8 mg/kg) or saline, each combined with mindfulness-based psychological support (PS) or alcohol psychoeducation (PE). We re-expressed the trial data on endpoints acceptable to regulators and compared the most and least intensive arms. Across pooled weeks 17-24, ketamine plus PS gave 78.5% versus 57.8% days abstinent (difference, 20.7 percentage points; P = .032); adjusted for baseline, the difference at weeks 21-24 was 26.9 percentage points (P = .011). At weeks 21-24, 50.0% versus 26.1% had no heavy drinking days (P = .127). Relative reductions in heavy drinking days were 55% in KARE, against 25%, -17%, 46% and 35% reported for naltrexone, exenatide, semaglutide and pemvidutide. These post hoc differences, measured 4 to 6 months after a 4 week course ended, are of magnitude similar to agents requiring continuous administration.

Resultado principalLimitación que admiten los autores

Apareció: martes, 29 de septiembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.09.26.26363761